Publications by authors named "Mathieu Virazels"
Resistance to immune checkpoint inhibitors (ICI) in cancer patients is not fully understood, and predictive biomarkers are lacking. MELANFα (NCT03348891) is an open-label, prospective, multicenter cohort of 60 patients with advanced melanoma receiving ICI (bitherapy: ipilimumab + nivolumab; monotherapy: pembrolizumab or nivolumab). The primary objective was to evaluate whether changes in plasma TNF between baseline (W0) and week 12 (W12) identified patients with non-progressive disease at W12.
View Article and Find Full Text PDFCombining TNF blockade with immune checkpoint inhibitors in patients with cancer.
Nat Rev Rheumatol
September 2021
Article Synopsis
- TNF blockers, specifically infliximab and certolizumab, are being tested for their ability to manage gastrointestinal side effects in patients with advanced melanoma receiving nivolumab and ipilimumab therapies.
- The TICIMEL clinical trial enrolled 14 patients and aimed to evaluate both the safety and effectiveness of these drug combinations, revealing that adverse effects were generally lower with infliximab treatment.
- Results indicated that while both combinations were safe, the certolizumab group demonstrated a high objective response rate, warranting further research into its clinical benefits.
Cutaneous melanoma is a deadly skin cancer whose aggressiveness is directly linked to its metastatic potency. Despite remarkable breakthroughs in term of treatments with the emergence of targeted therapy and immunotherapy, the prognosis for metastatic patients remains uncertain mainly because of resistances. Better understanding the mechanisms responsible for melanoma progression is therefore essential to uncover new therapeutic targets.
View Article and Find Full Text PDF